| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BioMarin: FDA Accepts For Priority Review PALYNZIQ SBLA To Expand Use To Adolescents Aged 12-17 | 214 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced the FDA has accepted for Priority Review the company's PALYNZIQ supplemental Biologics License Application to expand treatment... ► Artikel lesen | |
| Mi | Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies | 210 | AFX News | WASHINGTON (dpa-AFX) - Wednesday, Regeneron Pharmaceuticals, Inc. (REGN) and ModeX Therapeutics Inc., an OPKO Health company (OPK) entered into a license and collaboration agreement to discover... ► Artikel lesen | |
| Mi | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | 209 | Dow Jones News | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
29-Oct-2025 / 13:02 GMT/BST
... ► Artikel lesen | |
| Mi | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 204 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| Mi | Compass Pathfinder Limited: Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors | 194 | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey... ► Artikel lesen | |
| Mi | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group | 163 | GlobeNewswire (Europe) | ADAS-Cog13 difference -12.78 (P 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring impaired Autophagy - preceding amyloid-beta and tau NEW YORK, Oct. 29, 2025... ► Artikel lesen | |
| Mi | Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing | 154 | PR Newswire | REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and... ► Artikel lesen | |
| Mi | AnaptysBio, Inc.: Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation | 118 | GlobeNewswire (Europe) | New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy... ► Artikel lesen | |
| Mi | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 | 116 | GlobeNewswire (Europe) | Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically... ► Artikel lesen | |
| Mi | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | 69 | PR Newswire | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| GILEAD SCIENCES | 102,20 | 2,68 | +2,62 % | 0,79 | 15.09.2025 | |
| ROYALTY PHARMA | 31,430 | 0,75 | +2,39 % | 0,22 | 14.11.2025 | |
| ASTRAZENECA PLC ADR | 71,50 | 1,35 | +1,89 % | 0,52 | 08.08.2025 | |
| GRIFOLS | 11,430 | 0,15 | +1,31 % | 0,15 | 11.08.2025 | |
| IONIS PHARMACEUTICALS | 62,32 | 0,00 | 0,00 % | |||
| BIOGEN | 127,95 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 29,360 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 30,600 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 11,185 11,445 | -0,260 -2,27 % | 29.10. | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 11,410 11,970 | -0,560 -4,68 % | 29.10. | ||
| 89BIO INC A2PUP8 NASDAQ | 14,855 14,835 | 0,000 0,00 % | 29.10. | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 4,891 4,827 | +0,064 +1,33 % | 29.10. | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 4,350 4,405 | 0,000 0,00 % | 29.10. | ||
| AC IMMUNE SA A2AR5F Tradegate | 3,370 3,110 | +0,260 +8,36 % | 29.10. | ||
| ACADIA PHARMACEUTICALS INC 603035 Tradegate | 19,190 19,390 | -0,200 -1,03 % | 29.10. | ||
| ACRIVON THERAPEUTICS INC A3DXE7 NASDAQ | 1,890 1,980 | -0,090 -4,55 % | 29.10. | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 14,720 14,520 | +0,200 +1,38 % | 29.10. | ||
| ADMA BIOLOGICS INC A12FAG NASDAQ | 15,520 15,600 | -0,010 -0,06 % | 29.10. |